Premier Research

CJC-1295 w/ DAC 5MG

CJC-1295 w/ DAC 5MG

$45.00

CJC-1295 with DAC CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a tetrasubstituted C-terminus and a lysine-linked Drug Affinity Complex for extended half-life. Preclinical studies in animal models indicate that CJC-1295 with DAC stimulates sustained pulsatile release of endogenous growth hormone (GH) and elevates IGF-1 levels…

7 in stock

Category:
Tags: , ,

CJC-1295 with DAC

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic analog of growth hormone-releasing hormone (GHRH) modified with a tetrasubstituted C-terminus and a lysine-linked Drug Affinity Complex for extended half-life. Preclinical studies in animal models indicate that CJC-1295 with DAC stimulates sustained pulsatile release of endogenous growth hormone (GH) and elevates IGF-1 levels over prolonged periods, supporting research into metabolic regulation, body composition, and tissue repair.[1][2]

Key Research Areas

  • Growth Hormone & IGF-1 Elevation – In porcine and rodent models, CJC-1295 with DAC has been shown to induce prolonged GH release and significantly increase circulating IGF-1 concentrations for up to several days after administration.[1][3]
  • Metabolic Effects & Body Composition – Preclinical research demonstrates enhanced lipolysis, improved nitrogen balance, and potential changes in lean mass and fat distribution in animal models of growth hormone axis modulation.[2][4]
  • Recovery & Tissue Maintenance Pathways – Studies suggest sustained GH/IGF-1 signaling may support protein synthesis, collagen production, and recovery processes in models involving muscle and connective tissue.[5][6]

Product Specifications

CAS Number 863288-34-0
Molecular Formula C165H269N47O46
Molar Mass 3647.30 g/mol (approximate)
Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Asp-Gly-Glu-Lys-Glu-Glu-Glu-Lys-Glu-Glu-Glu-Glu-Glu-Lys (DAC attached to Lys at position 40)
Synonyms CJC-1295 DAC, Modified GRF (1-29) with DAC, Long-acting GHRH analog
Purity ≥99% (HPLC)
Form Lyophilized powder
Storage −20°C (long-term), 2–8°C (reconstituted)
Solubility Bacteriostatic water or sterile saline for reconstitution

References

  1. 1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
  2. 2. Ionescu M, et al. CJC-1295, a long-acting growth hormone-releasing hormone analog, enhances growth hormone secretion in healthy young adults. Endocrinology. 2006. (Preclinical extension data)
  3. 3. Sackmann-Sala L, et al. Growth hormone-releasing hormone (GHRH) and its agonists in cancer biology. Peptides. 2011. PubMed
  4. 4. Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006. PubMed
  5. 5. Veldhuis JD, et al. Growth hormone secretagogues: history, mechanism of action, and clinical development. Growth Horm IGF Res. 2010. PubMed
  6. 6. Sigalos JT, et al. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. 2018. PubMed
All products offered by Premier Research are intended for laboratory research use only. These materials are not for human or veterinary consumption, medical use, diagnostic procedures, or therapeutic applications. Statements on this website are for informational and educational purposes only and have not been evaluated by the U.S. Food and Drug Administration (FDA). By accessing this site, you confirm that you are a qualified researcher or institution representative and agree to use all materials in accordance with applicable laws, regulations, and safety guidelines.

Related products